Increasing Incidence of Chronic Diseases is Expected to Drive the Growth of Asia-Pacific Preclinical Imaging Market

Preclinical imaging refers to the use of various imaging modalities to visualize and study the biological processes in animals before  clinical trials. These systems help researchers to gain insight about disease mechanisms, evaluate potential drug candidates, and monitor treatment efficacy. Technology advancement in the field of imaging is playing a crucial role in driving the growth of the Asia-Pacific preclinical imaging market.

Modern imaging technologies, such as high-resolution magnetic resonance imaging (MRI), micro-computed tomography (micro-CT), and advanced ultrasound provide researchers with clearer and more detailed images of biological structures. The integration of multimodal imaging systems is an another advancement in preclinical imaging market as these systems combine multiple imaging techniques, such as PET-CT or PET-MRI, to provide complementary information and enhance the accuracy of preclinical studies which allows researchers to investigate multiple aspects of a disease or treatment simultaneously, leading to more comprehensive and reliable results.

Access Full Report @ https://www.databridgemarketresearch.com/pt/reports/asia-pacific-preclinical-imaging-market

Data Bridge Market Research analyzes that the Asia-Pacific Preclinical Imaging Market is expected to grow with a CAGR of 5.5% in the forecast period from 2023 to 2030, and is expected to reach USD  396,436.69 thousand by 2030 from USD 264,195.80 thousand in 2022.  

Key Findings of the Study

Increasing Incidence of Chronic Diseases

Chronic diseases, such as cancer, cardiovascular diseases, and neurological disorders, are a significant burden on healthcare systems worldwide. Preclinical imaging plays a vital role in understanding the underlying mechanisms of these diseases and developing effective therapeutic interventions.

Preclinical imaging offers valuable insights into disease progression, treatment response, and the evaluation of potential drug candidates. It allows researchers to visualize and study biological processes in animal models, providing a better understanding of disease mechanisms and aiding in the development of targeted therapies. Preclinical imaging helps in streamline the drug development process and reduces the risk of failure in clinical trials by non-invasively monitoring disease progression and treatment efficacy.

The increasing incidence of chronic diseases has created a strong demand for innovative and effective treatment options. Pharmaceutical companies and research institutions are leveraging preclinical imaging technologies to accelerate the development of novel therapies. Imaging modalities such as micro-CT, MRI, and PET provide detailed anatomical and functional information, enabling researchers to track disease progression, evaluate treatment response, and assess the safety and efficacy of potential therapeutics.

Report Scope and Market Segmentation

Segment Analysis

The Asia-Pacific preclinical imaging market is segmented into four notable segments based on product, reagents, application, and end user.      

• On the basis of product, the market is segmented into systems and services.

In 2023, the system segment is expected to dominate the Asia-Pacific preclinical imaging market

In 2023, the systems segment is expected to dominate the market as it provides comprehensive, integrated, and efficient imaging solutions that facilitate multimodal imaging and enhance the research capabilities of scientists in preclinical studies. This segment is expected to dominate with market share of 75.25%.

• On the basis of reagents, the market is segmented into preclinical optical imaging reagents, preclinical nuclear imaging reagents, preclinical MRI contrast agents, preclinical ultrasound contrast agents, and preclinical CT contrast agents.

In 2023, the preclinical optical imaging reagents segment is expected to dominate the Asia-Pacific preclinical imaging market

In 2023, the preclinical optical imaging reagents segment is expected to dominate as it provides non-invasive, real-time, and targeted visualization of specific molecules and cellular processes in small animals. This segment is expected to dominate with market share of 48.19%.

• On the basis of application, the market is segmented into research and development, drug discovery, bio-distribution, cancer cell detection, bio-markers, and others. In 2023, research and development segment is expected to dominate the market with a market share of 41.05%
• On the basis of end user, the market is segmented into contract research organization, pharmaceutical & biotech companies, academic & government research institutes, diagnostics center, and others. In 2023, the contract research organization segment is expected to dominate the market with a share of 54.78%  

Major Players

Data Bridge Market Research analyses PerkinElmer Inc. (U.S.), FUJIFILM Visualsonics, Inc (A Subsidiary of FUJIFILM Corporation) (Japan), Hologic, Inc. (U.S.), Bruker (Germany), Zeiss Group (Germany) as major market players in this market.

Market Developments

• In November 2022, Bruker announced the acquisition of Inscopix, Inc., a neuroscience pioneer and market leader of miniaturized microscopes, known as miniscopes, for freely moving animal brain imaging. This helped the organization develop more revenue
• In May 2022, FUJIFILM Corporation announced the launch of Vevo F2, the world’s first ultra-high to low frequency (71MHz-1MHz) ultrasound and photoacoustic imaging system for preclinical use. The Vevo F2 features HD image processing technology and introduces a completely new signal pathway – from transducer to display screen. This enabled better image clarity, and when combined with multi-line processing, delivers significantly improved frame rates over earlier generation platforms
• In April 2022, PerkinElmer, Inc. announced the expansion of its in vivo imaging portfolio with the launch of the Vega imaging system. This increased the company's product portfolio and overall revenue
• In December 2021, Battery Ventures, a Asia-Pacific, technology-focused investment firm, acquired LI-COR Biosciences, an industry-leading company that makes highly engineered instrumentation systems for environmental research, agriculture, drug discovery, protein research, and therapeutics development
• In October 2021, MR Solutions announced the launch of a new AI that revolutionizes Magnetic Resonance Imaging (MRI) for preclinical research. This helped the organization develop more revenue

Regional Analysis

Geographically, the countries covered in the market report are Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific. 

As per Data Bridge Market Research analysis:

China is expected to be dominate and fastest growing country in Asia-Pacific preclinical imaging market

China is expected to dominate and fastest growing country in the market due to the higher level of investments by various manufacturers and increasing technological advancements in the region. China will continue to dominate the Asia-Pacific Preclinical Imaging market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period.

For more detailed information about the Asia-pacific preclinical imaging market report, click here – https://www.databridgemarketresearch.com/pt/reports/asia-pacific-preclinical-imaging-market